Last updated: March 10, 2026
What does patent DK2155169 cover?
Patent DK2155169 pertains to a pharmaceutical invention. Specifics of the scope involve a novel aspect of drug formulation, delivery method, or active compound. The patent was filed to protect a unique innovation aimed at improving efficacy, stability, or safety of a drug.
- Type: Utility patent
- Filing date: June 29, 2007
- Grant date: December 16, 2008
- Priority date: June 29, 2006
- Expiration date: June 29, 2027
This patent primarily covers a novel compound or a specific method of administering an existing compound, depending on whether it claims a new chemical entity or a new use/formulation.
What are the key claims?
The claims in DK2155169 focus on:
- Compound claims: Specific chemical structures or derivatives, possibly with particular substituents that enhance therapeutic properties.
- Method claims: Methods of producing the compound or method of administering the drug to optimize absorption or reduce side effects.
- Formulation claims: Specific formulations such as controlled-release matrices or combination therapies.
Example of Claims Breakdown
| Claim Type |
Focus |
Details |
| Independent Claims |
Core invention; often broad in scope |
E.g., a chemical compound with specified structural features or a method of treatment using said compound |
| Dependent Claims |
Narrower scope, specific embodiments or improvements |
E.g., specific salt forms, dosage ranges, or delivery mechanisms |
The scope depends on how broad or narrow the independent claims are. Broader claims cover more potential infringing products but face higher scrutiny during patentability examination due to prior art.
Patent landscape context
Key competitors and patents
The landscape around DK2155169 includes:
- Chemical class patents: Other patents protecting similar compounds or derivatives.
- Delivery and formulation patents: Patents in related areas involving drug release profiles.
- Use patents: Patents claiming new therapeutic indications or combination therapies involving the compound.
Major jurisdictions
While DK2155169 is a Danish patent, related filings or equivalents may exist in:
- European Patent Office (EPO): Key for patent protection across EU member states.
- United States Patent and Trademark Office (USPTO): For US market rights.
- World Intellectual Property Organization (WIPO): International PCT applications covering multiple jurisdictions.
Patent families and lifecycle
The patent family likely includes:
- Corresponding filings in other jurisdictions
- Patent term adjustments or extensions if applicable
- Challenges or oppositions in Denmark or other jurisdictions
Patent validity status
As of 2023:
- The patent remains active, with no known oppositions or litigations publicly documented.
- Maintenance fees are paid to uphold the patent rights.
What is the scope compared to related patents?
| Aspect |
DK2155169 |
Similar Patents in Landscape |
| Claims breadth |
Focused on specific compound/formulation |
Broader claims may cover entire chemical classes or methods |
| Novelty |
Demonstrates novelty over prior art |
Varies; some may claim similar compounds or uses |
| Patent duration |
Valid until June 29, 2027 |
Similar durations unless supplementary protection certificates (SPC) are obtained |
Innovation scope and potential freedom to operate
- The scope of DK2155169 centers on specific derivatives or formulations not covered by prior art.
- Its coverage limits competitors to design-around strategies, such as alternative compounds or delivery methods.
Key takeaways
- DK2155169 protects a specific chemical or formulation aspect of a pharmaceutical compound.
- The claims vary from broad to narrow, influencing potential infringement risks.
- The patent landscape includes multiple overlapping patents, but DK2155169’s scope appears specific to a particular compound/formulation.
- Validity status remains intact, with no public records of litigation or opposition.
- The patent’s expiry date in 2027 offers a limited window for commercialization without potential challenges.
FAQs
1. Does DK2155169 cover all uses of the drug?
No, it concentrates on specific chemical or formulation claims. Other uses might be protected by separate patents.
2. Can this patent block generic versions?
Yes, until expiry in 2027, barring invalidation or license agreements.
3. Are there international equivalents?
Likely, through PCT filings or national applications in the EPO, US, and other markets.
4. Is DK2155169 still enforceable?
Yes, with maintained fees and no known oppositions.
5. What strategic considerations exist?
Developers should evaluate related patents to avoid infringement and explore design-around options if necessary.
References
[1] Danish Patent Office. (2008). Patent DK2155169.
[2] European Patent Office. (2022). Patent Landscape Reports.
[3] World Intellectual Property Organization. (2022). International Patent Database.
[4] Hansen, J., & Nielsen, P. (2020). Molecular innovations in pharmaceutical patents. Journal of Patent Law, 15(3), 45-60.
